Evidence map›Paper›PMID 25228695›Full record

ArticleThe Journal of biological chemistry2014

Identification of 14-3-3β gene as a novel miR-152 target using a proteome-based approach.

Simon Jasinski-Bergner, Franziska Stehle, Evamaria Gonschorek, Jana Kalich, Kristin Schulz, Stefan Huettelmaier, Juliane Braun, Barbara Seliger

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Simon Jasinski-BergnerFrom the Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle and.
Franziska StehleFrom the Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle and.
Evamaria GonschorekFrom the Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle and.
Jana KalichFrom the Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle and.
Kristin SchulzFrom the Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle and.
Stefan Huettelmaierthe Institute of Molecular Medicine, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.
Juliane Braunthe Institute of Molecular Medicine, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.
Barbara SeligerFrom the Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle and barbara.seliger@uk-halle.de.
Martin Luther University Halle-Wittenberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies demonstrated that miR-152 overexpression down-regulates the nonclassical human leukocyte antigen (HLA) class I molecule HLA-G in human tumors thereby contributing to their immune surveillance. Using two-dimensional gel electrophoresis followed by MALDI-TOF mass spectrometry, the protein expression profile of HLA-G(+), miR-152(low) cells, and their miR-152-overexpressing (miR(high)) counterparts was compared leading to the identification of 24 differentially expressed proteins. These were categorized according to their function and localization demonstrating for most of them an important role in the initiation and progression of tumors. The novel miR-152 target 14-3-3 protein β/α/YWHAB (14-3-3β) is down-regulated upon miR-152 overexpression, although its overexpression was often found in tumors of distinct origin. The miR-152-mediated reduction of the 14-3-3β expression was accompanied by an up-regulation of BAX protein expression resulting in a pro-apoptotic phenotype. In contrast, the reconstitution of 14-3-3β expression in miR-152(high) cells increased the expression of the anti-apoptotic BCL2 gene, enhances the proliferative activity in the presence of the cytostatic drug paclitaxel, and causes resistance to apoptosis induced by this drug. By correlating clinical microarray data with the patients' outcome, a link between 14-3-3β and HLA-G expression was found, which could be associated with poor prognosis and overall survival of patients with tumors. Because miR-152 controls both the expression of 14-3-3β and HLA-G, it exerts a dual role in tumor cells by both altering the immunogenicity and the tumorigenicity.

Indexed as

Gene Expression Regulation, Neoplastic14-3-3 ProteinsApoptosisCell Line, TumorCell ProliferationCell SurvivalHEK293 CellsHLA-C AntigensHLA-G AntigensHumansMass SpectrometryMicroRNAsNeoplasmsOligonucleotide Array Sequence AnalysisPaclitaxelProteome14-3-3 ProteinsHLA-C AntigensHLA-G AntigensMicroRNAsMIRN152 microRNA, humanPaclitaxelProteomeYWHAB protein, human14-3-3βCell BiologyHLA-GImmunologyMicroRNA (miRNA)miR-152OncogeneTumor Immunology

Identifiers

PMID25228695
PMCPMC4223316
OpenAlexW2029268657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.